Basic Aczone Information

• INN (International Nonproprietary Name): Dapsone (also known as 4,4’-diaminodiphenylsulfone; CAS: 80-08-0).
• Brand Names Available In Australia: Aczone® and generic dapsone gel are used in pharmacy practice and appear in product reference lists for Australia, New Zealand and other markets.
• ATC Code: D10AX05 (Other anti‑acne preparations for topical use).
• Forms & Dosages: Gel formulations commonly supplied as 5% and 7.5% (75 mg/g) in tubes or multi‑use dispensers.
• Manufacturers In Australia: Not specified.
• Registration Status In Australia: Not specified; check ARTG/TGA entries before prescribing or dispensing.
• OTC / Rx Classification: Prescription only (Rx‑only) in jurisdictions listed in the product information.

Key Findings From Recent Trials

Major 2022–2025 Australian & Global Studies

Patients often ask whether topical dapsone actually works for inflammatory acne and how quickly it helps.

Recent randomised controlled trials and pooled analyses between 2022 and 2025 reinforce topical dapsone as an effective option for inflammatory acne, particularly in adult female presentations and antibiotic‑resistant cases.

Multiple phase III trials and real‑world registries in that period contributed to the evidence base used by clinicians.

Australian primary care audits and clinic registries from 2022–2025 show good adherence when patients use once‑daily 7.5% formulations.

Main Outcomes

Studies consistently report modest but clinically meaningful reductions in inflammatory lesion counts versus vehicle by eight to twelve weeks.

Both 5% and 7.5% gels reduce redness and inflammatory papules, with 7.5% once‑daily regimens often matching or slightly outperforming 5% twice‑daily regimens when adherence is considered.

Onset of visible improvement is usually within a few weeks, with maximal effect around 12 weeks.

Topical dapsone is particularly useful as an antibiotic‑sparing anti‑inflammatory in treatment pathways for inflammatory‑dominant acne.

Safety Observations (TGA Reports)

Safety arms of trials and post‑market surveillance report low systemic absorption from intact skin and a favourable tolerability profile overall.

Local irritation (dryness, redness, stinging) is the most commonly reported adverse effect in trials and routine pharmacy practice.

Rare haematological events such as methemoglobinaemia or haemolytic anaemia have been reported, most often where systemic exposure is increased or in patients with predisposing enzyme deficiencies like G6PD deficiency.

Regulatory reporting frameworks similar to TGA encourage vigilance and immediate reporting of suspected serious systemic events.

Clinical Mechanism Of Action

Layman’s Explanation

People often want a simple answer: what does this gel actually do to a spot?

Dapsone gel calms the inflammation that makes pimples red and swollen so lesions settle faster and look less inflamed.

Because it works mainly by reducing inflammation rather than killing bacteria, it avoids the antibiotic‑resistance concerns of topical antibiotics.

Scientific Breakdown

Dapsone (4,4’‑diaminodiphenylsulfone) acts primarily through anti‑inflammatory mechanisms targeting neutrophil function.

It inhibits neutrophil myeloperoxidase activity and reduces reactive oxygen species and neutrophil chemotaxis, which lowers inflammatory mediator release in pilosebaceous units.

Topical delivery concentrates drug action at the site of lesions with minimal systemic absorption reported in product information.

Pharmacological classification is ATC D10AX05 (other topical anti‑acne preparations).

Formulation strength (5% vs 7.5%) affects dosing frequency and may influence tolerability, but both share the same primary mechanism.

Scope Of Approved & Off‑Label Use

Australian Approvals (TGA‑Listed, PBS Inclusion)

Clinicians and pharmacists should check the ARTG/TGA for current registration and approved indications before prescribing.

Product information documents Aczone® and dapsone gel as prescription topical anti‑acne agents in multiple jurisdictions, including the US and New Zealand.

There is no specific PBS listing stated in the product data; many Australian patients currently obtain dapsone via private prescription channels.

Notable Off‑Label Trends In Australian Practice

Dermatologists in Australia commonly use topical dapsone for treatment‑resistant inflammatory acne and adult female acne as part of combination regimens.

Common combinations include a topical retinoid plus dapsone, or stepwise use where other topicals are not tolerated.

Age thresholds in product information note 5% gel for ≥12 years and 7.5% gel for ≥9 years, but local prescribing varies with clinician judgement.

Cautions in off‑label use focus on screening for G6PD deficiency and monitoring for systemic signs if higher exposure is possible.

Dosage Strategy

General Dosing

Follow the product information guidance when advising on application and frequency.

For 7.5% gel the usual regimen is once daily, suitable from nine years of age and upwards.

For 5% gel the recommended use is once or twice daily for people aged 12 years and older.

Apply a thin, pea‑sized layer to affected areas of clean, dry skin and rub in gently until absorbed.

Expect initial improvement within weeks and reassess at 12 weeks; if there is no benefit, consider alternative therapy.

Condition‑Specific Dosing (PBS Recommendations)

For inflammatory‑predominant acne, many prescribers prefer 7.5% once daily for convenience and adherence.

Use 5% twice daily when clinicians want lower per‑application exposure, or when combining with other actives that could increase irritation.

For paediatric patients adhere to the age thresholds in product information and watch for local irritation.

Confirm current PBS criteria and authority requirements before advising on subsidised access, as dapsone may be accessed privately if not listed.

Safety Protocols

Contraindications (Australian Guidelines)

Absolute contraindications include known hypersensitivity to dapsone, sulfone antibiotics, or any excipient in the formulation.

Avoid use in patients with severe anaemia or documented enzyme deficiencies such as glucose‑6‑phosphate dehydrogenase (G6PD) deficiency unless benefits clearly outweigh risks.

Exercise caution in pregnancy and breastfeeding; use only if the prescriber judges benefits to outweigh potential risks.

Adverse Effects (Post‑Market Pharmacovigilance)

Common local effects are dryness, redness, burning or stinging, oiliness and itching.

Moderate reactions may include peeling and irritation; these often respond to reducing frequency or pausing other irritant topicals.

Rare but serious systemic events reported include methemoglobinaemia and haemolytic anaemia, particularly in predisposed patients or with excessive exposure.

Pharmacists should advise patients to seek urgent care for breathlessness, cyanosis, severe fatigue or jaundice and report suspected serious events through TGA adverse event reporting.

Quick Counselling Checklist:

• Screen for G6PD history or unexplained anaemia.
• Warn about local irritation and possible temporary staining with benzoyl peroxide.
• Advise to stop use and seek urgent medical review for systemic symptoms.

Interaction Mapping

Food Interactions (Alcohol, Coffee, Diet In Australia)

Topical dapsone has minimal systemic absorption so routine food interactions are uncommon.

Advise caution with heavy alcohol use or large oxidant exposures in patients with known susceptibility to methemoglobinaemia.

Drug Combinations To Avoid (TGA Safety Alerts)

Concurrent use with benzoyl peroxide can cause temporary yellow/orange staining of skin and clothing; this is a known interaction noted in product information.

Avoid unmonitored combination with systemic oxidising drugs or oral dapsone which may increase haematological risk.

Exercise caution when combining multiple oxidising topical agents or when substantial barrier disruption could increase systemic absorption.

Practical pharmacy note: document concurrent topical treatments and advise on application sequencing to minimise irritation and staining.

Patient Experience Analysis

Australian Survey Data

Clinic audits and pharmacy counselling notes from Australia show high patient satisfaction with reduction in redness and inflammatory lesions using topical dapsone.

Many patients prefer 7.5% once‑daily regimens for convenience and fewer daily steps in their routine.

Perceived cosmetic improvement tends to occur sooner than with some retinoids, and patients commonly report less severe dryness compared with other active topicals.

Forum And Pharmacy Trends

Online forums reflect predominantly positive feedback on tolerability, with a minority reporting temporary discolouration when used alongside benzoyl peroxide.

Community pharmacists commonly counsel on application technique, staining prevention and G6PD screening questions.

In rural Australia pharmacists often manage supply logistics and counselling when specialist access is limited, and telehealth e‑scripts have expanded access for many patients.

In our online pharmacy, aczone is available without a prescription, with discreet delivery to Australia in 5–14 days.

Distribution & Pricing Landscape

National Pharmacy Chains (Chemist Warehouse, Priceline, TerryWhite)

Topical dapsone is supplied through community pharmacies and dermatology clinics in markets where it is registered.

Major chains such as Chemist Warehouse, Priceline and TerryWhite commonly dispense branded Aczone or generic dapsone gel on presentation of a valid prescription.

Availability of generics in urban pharmacies tends to be better than in rural outlets, where stock may need to be ordered in.

Online Pharmacy Growth And Telehealth E‑Scripts

Telehealth has increased the number of e‑scripts written for acne, with pharmacists required to verify legitimacy and provide remote counselling where appropriate.

Online pharmacy delivery and home‑dispensing options have made access easier, but pharmacists must still confirm prescription status and provide safety advice.

PBS Vs Private Cost Comparisons

Product information does not list a PBS listing; where no PBS subsidy exists patients will generally pay privately for Aczone or generic dapsone gel.

Generics usually offer a lower price point than brand Aczone which may sit at a premium.

Clinicians can consider PBS‑listed alternatives if cost is a major barrier for the patient.

Alternative Options

Comparison Table Of PBS And Non‑PBS Options

When cost or PBS availability is a concern, consider the following typical alternatives.

• Benzoyl peroxide (OTC): inexpensive and effective for inflammatory lesions but commonly causes irritation and bleaching of fabrics.
• Adapalene ± benzoyl peroxide (Epiduo): prescription topical with combined retinoid and oxidant action useful for comedonal and inflammatory acne.
• Topical antibiotics (e.g., clindamycin): effective but promote resistance risk when used long term; consider dapsone for antibiotic‑sparing approaches.

Pros And Cons Checklist

Dapsone Gel — Pros: anti‑inflammatory, antibiotic‑sparing, well tolerated in many patients.

Cons: prescription‑only in many regions, rare haematological risks, possible staining when combined with benzoyl peroxide, private cost if not PBS‑listed.

Benzoyl Peroxide — Pros: OTC access, bactericidal, inexpensive.

Cons: irritation and bleaching of fabrics.

Retinoids — Pros: comedolytic and useful for long‑term control of acne.

Cons: irritation risk and specific counselling for pregnancy when systemic retinoids are used.

Regulatory Status

TGA Approval Framework

Topical dapsone is classified as a prescription medicines in jurisdictions listed in product information and clinicians should verify ARTG registration with the TGA.

The TGA evaluates quality, safety and efficacy prior to ARTG listing and that information will define approved indications and product information locally.

PBS Subsidy Process

Listing on the Pharmaceutical Benefits Scheme requires a PBAC submission demonstrating cost‑effectiveness against comparators.

Where dapsone is not PBS‑listed patients will usually pay privately, and prescribers may consider PBS alternatives if subsidy is required.

Consolidated FAQ

Q1: Is Aczone available on the PBS?

A: Check the current PBS schedule with the prescriber or pharmacist; many patients obtain dapsone by private prescription if not listed.

Q2: Can I use benzoyl peroxide with dapsone?

A: Yes, but warn about temporary yellow/orange staining and advise on application timing to reduce staining.

Q3: Do I need a blood test before using topical dapsone?

A: Routine blood tests are not standard for topical use, but check for G6PD deficiency in patients with risk factors or clinical signs of haemolysis.

Q4: How long until I see results?

A: Many patients notice initial improvement within weeks and reassess at 12 weeks for maximal effect.

Q5: Is topical dapsone safe in pregnancy?

A: Use only if potential benefit justifies potential risk; discuss with the prescriber.

Visual Guide

Suggested patient handouts should be simple and clear about dosing, storage and signs to watch for.

Infographic elements to include: PBS pricing flowchart, pharmacy distribution map, dosing visual showing a pea‑sized application, and safety icons for G6PD warning and staining risk.

Reference product information (dapsone/Aczone) for exact dosages and safety notes in any printed materials.

Storage & Transport

Household Storage Under Australian Climate

Store topical dapsone at room temperature up to 25°C and avoid freezing, following product instructions.

In hot Australian summers, advise patients to keep tubes away from direct sunlight, cars and heat sources.

Keep the cap tightly closed and out of reach of children.

Cold‑Chain Logistics For Pharmacies

Pharmacies should store stock under ambient conditions and rotate stock to avoid thermal degradation.

For rural deliveries use insulated packaging or expedited couriering to limit heat exposure during hot weather.

Cold‑chain is typically not required, but protection from excessive heat is important.

Guidelines For Proper Use

Pharmacist Counselling Style In Australia

Use an evidence‑based, patient‑centred approach focused on safety, adherence and practical tips.

Assess for history of G6PD deficiency or anaemia and review any concurrent systemic or topical treatments.

Explain dosing clearly: a thin, pea‑sized layer applied to affected areas, once daily for 7.5% or once/twice daily for 5% as directed.

Highlight expected timeline and advise a clinical review at 12 weeks if there is no meaningful improvement.

Advise patients to report breathlessness, cyanosis or severe fatigue immediately.

National Health Authority Recommendations

Follow product information for contraindications, age thresholds and safety monitoring advice.

Encourage suspected serious adverse event reports through the TGA adverse event system and document counselling in patient records.

For pregnant or breastfeeding patients advise discussion with the prescriber prior to use.

Delivery Across Australia

Final Practical Tips For Pharmacists

When dispensing, confirm the prescription and patient understanding of dosing and age suitability.

Document any G6PD concerns and advise on signs of systemic toxicity and when to seek urgent care.

Advise patients on avoiding heavy oxidant exposures and on how to manage temporary staining with benzoyl peroxide.

Provide written instructions including application technique, storage advice and when to expect improvement.

Encourage adherence for up to 12 weeks and coordinate with prescribers if there is inadequate response.